Genetic Technologies Receives Nasdaq Notification Regarding Minimum Bid Price DeficiencyGlobeNewsWire • 07/21/23
Genetic Technologies Announces Closing of $5 Million Registered Direct OfferingGlobeNewsWire • 02/07/23
Genetic Technologies to Launch Ground-breaking Comprehensive Risk Test for Breast & Ovarian CancerGlobeNewsWire • 02/06/23
GENE to Launch World's First Comprehensive Risk Test for Breast & Ovarian CancerGlobeNewsWire • 02/03/23
Quarterly Business Update – December 2022; Sixth Consecutive Quarter of GrowthGlobeNewsWire • 01/30/23
GeneType published in PLOS ONE – development of polygenic risk scores for cardiovascular diseases and type 2 diabetesGlobeNewsWire • 12/06/22
Genetic Technologies Announces Q1 FY23 Quarterly Results and Investor Webinar DetailsGlobeNewsWire • 10/25/22
Genetic Technologies Limited Interview to Air on Bloomberg U.S. on the RedChip Money Report(R)Accesswire • 10/13/22
Journal of Precision Medicine publication confirms GeneType Risk Test outperforms traditional risk assessments for breast cancerGlobeNewsWire • 09/29/22
Completion of AffinityDNA Acquisition expanding global direct-to-consumer businessGlobeNewsWire • 07/14/22